Giant Biogene Holding Co. Ltd. (2367) AI Stock Analysis

• Market Cap: HK$61.13B
• Dividend Yield: 1.11%
• Average Volume (3M): 17.53M
• Price to Earnings (P/E): 26.0
• Beta (1Y): 0.99
• Revenue Growth: 54.44%
• EPS Growth: 35.90%
• Country: HK
• Employees: 1,758
• Sector: Healthcare
• Sector Strength: 39
• Industry: Household & Personal Products
• EPS (TTM): 1.15
• Shares Outstanding: 1,070,904,000
• 10 Day Avg. Volume: 15,707,826
• 30 Day Avg. Volume: 17,533,372
• PEG Ratio: 1.38
• Price to Book (P/B): 6.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 68.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$75.20
• Price Target Upside: 30.10% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 64 Neutral
• Price Target: HK$63.00 ▲(9.00%Upside)

The overall stock score is primarily driven by strong financial performance, highlighted by robust revenue growth and profit margins, and a stable balance sheet. Technical analysis indicates potential bearish trends, while valuation metrics suggest a fair market price with a moderate P/E ratio and low dividend yield. The absence of earnings call and corporate events data limits additional insights.

Giant Biogene Holding Co. Ltd. Business Overview & Revenue Model

Company Description

Giant Biogene Holding Co. Ltd. (2367) is a leading biotechnology company that specializes in the research, development, and commercialization of biotechnological products. The company operates primarily in the healthcare and cosmetic sectors, offering a diverse range of products including biomedical materials, skincare products, and other innovative solutions aimed at enhancing health and wellness.

How the Company Makes Money

Giant Biogene Holding Co. Ltd. generates revenue through the sale of its biotechnological products, particularly in the healthcare and cosmetic markets. The company's key revenue streams include the commercialization of biomedical materials used in medical applications and the sale of skincare products that leverage its proprietary biotechnology. Additionally, the company may engage in strategic partnerships and collaborations with other firms in the biotechnology and healthcare industries to enhance its product offerings and expand its market reach. These partnerships can contribute to its earnings by providing access to new markets, sharing research and development costs, and leveraging complementary technologies. Furthermore, Giant Biogene may also benefit from licensing agreements, where it can earn revenue by allowing other companies to use its patented technologies and products.

Giant Biogene Holding Co. Ltd. Financial Statement Overview

Summary

Giant Biogene Holding Co. Ltd. exhibits strong financial health with impressive revenue growth, high margins, and a solid balance sheet. The company's minimal debt and high equity ratio provide stability. However, the lack of cash flow data for 2024 raises questions about its liquidity trends.

Income Statement

The company has shown strong revenue growth over the years, with a significant increase from 2023 to 2024 (57%). Gross profit margins are consistently high, indicative of strong pricing power and cost management, with the most recent margin at 82%. Net profit margins are robust, reaching 37% in 2024, reflecting efficient operational management. EBIT and EBITDA margins are also strong, underlining operational efficiency.

Balance Sheet

The balance sheet reveals a solid equity position with a high equity ratio of 88% in 2024, indicating financial stability. The debt-to-equity ratio is very low, reflecting minimal leverage risk. Return on equity is impressive at 29%, showcasing effective utilization of shareholders' capital. However, the substantial increase in stockholders' equity warrants monitoring to ensure sustainable returns.

Cash Flow

Cash flow from operations was strong in 2023, although data for 2024 is not available. The free cash flow in 2023 was positive, contributing to the company's liquidity. The free cash flow to net income ratio is healthy at 97.7% in 2023, indicating efficient conversion of earnings into cash. However, the absence of cash flow data for 2024 limits a comprehensive analysis.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.54B	3.52B	2.36B	1.55B	1.19B
Gross Profit	4.55B	2.95B	2.00B	1.35B	1.01B
EBITDA	2.31B	1.78B	1.21B	938.78M	674.10M
Net Income	2.06B	1.45B	1.00B	828.13M	826.45M
Balance Sheet
Total Assets	8.04B	4.97B	3.14B	7.88B	2.65B
Cash, Cash Equivalents and Short-Term Investments	5.86B	3.78B	2.20B	7.26B	1.96B
Total Debt	6.71M	2.73M	2.59M	0.00	0.00
Total Liabilities	918.14M	602.03M	301.19M	6.86B	2.19B
Stockholders Equity	7.11B	4.36B	2.83B	1.02B	458.00M
Cash Flow
Free Cash Flow	1.79B	1.42B	778.39M	581.21M	757.79M
Operating Cash Flow	2.04B	1.65B	931.64M	692.40M	834.12M
Investing Cash Flow	-1.11B	-527.28M	-858.74M	1.56B	-521.12M
Financing Cash Flow	582.95M	51.81M	-5.79B	4.48B	-17.52M

Giant Biogene Holding Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 57.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2367, the sentiment is Neutral. The current price of 57.8 is above the 20-day moving average (MA) of 55.01, below the 50-day MA of 65.65, and below the 200-day MA of 57.98, indicating a neutral trend. The MACD of -1.63 indicates Negative momentum. The RSI at 51.82 is Neutral, neither overbought nor oversold. The STOCH value of 80.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2367.

Giant Biogene Holding Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2145	77 Outperform	HK$33.83B	38.53	37.28%	0.98%	59.83%	68.29%
6601	74 Outperform	€3.52B	15.96	6.78%	5.60%	9.45%	12.30%
1044	72 Outperform	$26.96B	10.62	11.12%	6.44%	-6.53%	-18.43%
2367	64 Neutral	HK$61.13B	26.02	36.16%	1.11%	54.44%	35.90%
Sector *	59 Neutral	HK$15.54B	5.61	-7.44%	4.07%	11.55%	-28.15%
6993	54 Neutral	HK$24.09B	―	-7.87%	2.92%	16.82%	-348.71%
0157	48 Neutral	HK$1.12B	―	-20.26%	―	5.25%	-581.58%

Giant Biogene Holding Co. Ltd. Corporate Events

Giant Biogene’s Controlling Shareholder Boosts Stake

Giant Biogene Holding Co., Ltd., a company incorporated in the Cayman Islands, has announced an increase in shareholding by its controlling shareholder, Juzi Holding Co., Ltd. This move is intended to demonstrate confidence in the company’s future development and promote sustainable growth. Juzi Holding has purchased 1,056,600 shares, raising its total ownership to 54.36% of the company’s issued shares. This strategic action is aimed at safeguarding public investors’ interests and may be subject to further increases based on market conditions.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

Giant Biogene’s Controlling Shareholder Increases Stake

Giant Biogene Holding Co., Ltd announced that its controlling shareholder, Juzi Holding Co., Ltd, has increased its shareholding by purchasing 922,600 shares at a total cost of HK$46.7 million. This move demonstrates confidence in the company’s future development and aims to promote its sustainable growth while safeguarding public investors’ interests. Juzi Holding now holds 54.35% of the company’s total issued shares and may further increase its stake, depending on market conditions.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

Giant Biogene Announces Special Cash Dividend for 2024

Giant Biogene Holding Co., Ltd. has announced a special cash dividend of RMB 0.5921 per share for the financial year ending December 31, 2024, with the payment to be made in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09357. This announcement reflects the company’s robust financial performance and commitment to delivering value to its shareholders, potentially enhancing its market position and investor confidence.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

Giant Biogene Announces AGM Results and Dividend Distribution

Giant Biogene Holding Co., Ltd held its Annual General Meeting on June 13, 2025, where all proposed resolutions were approved by shareholders. Key outcomes include the re-election of directors, re-appointment of Ernst & Young as auditors, and authorization for the board to manage share repurchases and issuances. Additionally, the company announced the distribution of a final and special dividend for the year ended December 31, 2024, reflecting strong shareholder support and financial stability.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

Giant Biogene Updates Final Dividend for 2024

Giant Biogene Holding Co., Ltd announced an update to its final cash dividend for the year ended December 31, 2024, with a declared dividend of RMB 0.6021 per share. The dividend will be paid in Hong Kong dollars at a rate of HKD 0.6584 per share, with the payment date set for August 29, 2025. This update reflects changes in the default currency and exchange rate, potentially impacting shareholders’ returns and the company’s financial distribution strategy.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

Giant Biogene’s Controlling Shareholder to Boost Investment

Giant Biogene Holding Co., Ltd announced that its controlling shareholder, Juzi Holding Co., Ltd, plans to increase its shareholding in the company by at least HK$200 million within the next three to six months. This move reflects Juzi Holding’s confidence in the company’s growth potential and commitment to its future prospects, while ensuring a sufficient public float of shares.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$93.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

Giant Biogene Announces Annual General Meeting with Key Resolutions

Giant Biogene Holding Co., Ltd. has announced its upcoming annual general meeting scheduled for June 13, 2025, in Xi’an, Shaanxi Province, China. The meeting will address several key resolutions, including the re-election of independent non-executive directors, re-appointment of Ernst & Young as auditors, and granting general mandates for share repurchase and issuance. These resolutions are expected to impact the company’s governance and financial strategies, potentially influencing its market positioning and shareholder value.

Giant Biogene Completes Share Placement and Subscription to Fund Expansion

Giant Biogene Holding Co., Ltd announced the completion of a Vendor Placing and Subscription of new shares under a general mandate. The company successfully placed 35,000,000 shares at HK$66.65 per share, raising approximately HK$2,294 million. The proceeds will be used to develop the company’s core business, including brand promotion, marketing, category expansion, and R&D investment, as well as to replenish liquidity and support general corporate purposes.

Giant Biogene Announces HK$2.294 Billion Share Placement and Subscription

Giant Biogene Holding Co., Ltd. announced a placing and top-up subscription agreement involving 35 million shares at HK$66.65 per share, expected to raise approximately HK$2,294 million in net proceeds. The funds will be used to enhance the company’s financial strength, market competitiveness, and shareholder base, supporting long-term sustainable development and liquidity.